MAPT and Alzheimer disease: Therefore, we tested if plasma biomarkers of AD (Aβ42/Aβ40 ratio and total-tau), neurodegeneration, and brain injury (Nf-L and GFAP) would show a greater association with TEMRAs than what was seen for cognitive status.